Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.02), Briefing.com reports. During the same quarter in the previous year, the business earned ($0.82) earnings per share.
Rocket Pharmaceuticals Trading Down 6.1 %
Shares of RCKT stock traded down $1.23 on Wednesday, hitting $18.90. The stock had a trading volume of 842,481 shares, compared to its average volume of 757,897. The company’s 50 day moving average price is $22.25 and its 200-day moving average price is $24.76. Rocket Pharmaceuticals has a 1 year low of $14.89 and a 1 year high of $32.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.47 and a quick ratio of 10.47. The firm has a market capitalization of $1.72 billion, a P/E ratio of -6.64 and a beta of 1.13.
Insider Activity at Rocket Pharmaceuticals
In related news, insider Mark Andrew White sold 3,026 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $20.39, for a total value of $61,700.14. Following the completion of the transaction, the insider now owns 72,220 shares in the company, valued at $1,472,565.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Rocket Pharmaceuticals news, CEO Gaurav Shah sold 9,790 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $23.35, for a total value of $228,596.50. Following the sale, the chief executive officer now owns 728,069 shares of the company’s stock, valued at approximately $17,000,411.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Andrew White sold 3,026 shares of the business’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $20.39, for a total value of $61,700.14. Following the transaction, the insider now directly owns 72,220 shares of the company’s stock, valued at $1,472,565.80. The disclosure for this sale can be found here. Insiders sold 15,755 shares of company stock worth $358,654 in the last three months. 31.10% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on RCKT
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Featured Stories
- Five stocks we like better than Rocket Pharmaceuticals
- 3 Small Caps With Big Return Potential
- What Are Bonds? A High-Level Overview
- Business Services Stocks Investing
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- Energy and Oil Stocks Explained
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.